Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race

Pfizer Inc.’s success with the launch of Ibrance (palbociclib) for metastatic breast cancer has shown the big pharma’s efforts to reinvent itself into an oncology leader are beginning to bear fruit. But Pfizer still has something to prove in oncology – that it can win in the fiercely competitive area of immuno-oncology, where the most spectacular advances against cancer and the biggest financial returns are expected to be made.

The year will hold important milestones in Pfizer’s efforts to advance what appears to be an impressive early pipeline of immuno-oncology assets toward the market and find the most efficacious regimens. Competing against the likes of Bristol-Myers Squibb Co., Roche, Merck & Co. Inc